IHC - Napsin A

The IHC – Napsin A test is an advanced immunohistochemistry (IHC) diagnostic test used to detect Napsin A protein expression in tissue samples. Napsin A is an aspartic proteinase primarily expressed in lung alveolar cells and certain kidney tissues. It is considered a highly valuable marker for identifying lung adenocarcinoma and determining tumor origin in pathology.

This test is commonly used when evaluating lung tumors and metastatic cancers of unknown primary origin. Detecting Napsin A helps pathologists distinguish primary lung adenocarcinoma from other lung cancers or metastatic tumors that may have spread from different organs.

The Napsin A test is often performed along with other immunohistochemical markers such as TTF-1, CK7, and p40 to improve diagnostic accuracy and provide detailed tumor classification.

Benefits of the Test

The Napsin A IHC test offers several clinical benefits:

• Detects Napsin A protein expression in tissue
• Supports diagnosis of primary lung adenocarcinoma
• Helps differentiate lung adenocarcinoma from squamous cell carcinoma
• Assists in identifying metastatic tumor origin
• Improves tumor classification accuracy
• Supports personalized treatment planning

This test is highly useful when microscopic findings are inconclusive.

Why Doctors Recommend This Test

Doctors recommend the Napsin A IHC test when lung cancer is suspected or when determining tumor origin is necessary.

It is commonly advised for:

• Suspected lung adenocarcinoma cases
• Patients with abnormal lung biopsy findings
• Metastatic tumors of unknown primary origin
• Cases requiring lung tumor subtype classification
• Oncology diagnostic evaluations for treatment planning

The results help oncologists confirm diagnosis and choose appropriate therapy.

Preparation Before Test

No special preparation is required from the patient. The test is performed on tissue biopsy or surgically removed tumor specimens already collected during standard diagnostic procedures.

Normal Reporting Time

The usual reporting time for the Napsin A IHC test is 2 to 4 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected lung adenocarcinoma
• Individuals with metastatic tumors of unknown origin
• Patients undergoing lung cancer evaluation
• Cases requiring advanced tumor classification
• Oncology patients needing personalized treatment planning

The IHC Napsin A test is an essential tool in modern pathology. It helps confirm lung adenocarcinoma diagnosis accurately and supports precise classification of lung tumors. Early and accurate diagnosis improves treatment outcomes and ensures better clinical management.